Recent research indicates that a ketogenic diet may enhance the effectiveness of certain treatments for pancreatic cancer. A study published in Nature in August 2024 by scientists at the University of California, San Francisco (UCSF) demonstrated that combining a high-fat, low-carbohydrate ketogenic diet with the experimental drug eFT508 (tomivosertib) led to significant tumor reduction in mice models of pancreatic cancer. The ketogenic diet altered the metabolism of cancer cells, making them more susceptible to the drug, which inhibits the protein eukaryotic translation initiation factor (eIF4E). 
University of California, San Francisco

Another study from March 2022 by the Translational Genomics Research Institute (TGen) found that a ketogenic diet, when combined with a triple-drug therapy (gemcitabine, nab-paclitaxel, and cisplatin), helped kill pancreatic cancer cells in laboratory experiments. The diet decreased glucose levels in tumors, effectively starving the cancer cells, and enhanced the efficacy of the chemotherapy regimen. 
News Medical

While these findings are promising, they are primarily based on preclinical studies involving animal models and laboratory experiments. Clinical trials are necessary.

Glutamine, a non-essential amino acid, plays a significant role in the metabolism and proliferation of pancreatic cancer cells. These cells often exhibit a high dependency on glutamine, utilizing it for energy production, biosynthesis of macromolecules, and maintenance of redox balance. This phenomenon, known as "glutamine addiction," makes glutamine metabolism a potential target for therapeutic intervention in pancreatic cancer.

Metabolic Support: Pancreatic cancer cells rely on glutamine as a carbon and nitrogen source, supporting the synthesis of nucleotides, amino acids, and lipids essential for rapid cell division. 

Elevated glutamine levels have been associated with aggressive clinical features in pancreatic cancer, including increased tumor growth and metastasis. Studies have shown that glutamine promotes the biosynthesis of carbohydrate antigen 19-9 (CA19-9), a biomarker linked to pancreatic cancer progression. 

Targeting Glutamine Metabolism: Given the reliance of pancreatic cancer cells on glutamine, strategies that inhibit glutamine uptake or metabolism are being explored. For instance, the use of glutamine analogs has shown promise in preclinical models by suppressing tumor growth. 

Combination Therapies: Combining glutamine metabolism inhibitors with other treatments, such as chemotherapy or targeted therapies, may enhance therapeutic efficacy. This approach aims to disrupt the metabolic flexibility of cancer cells, making them more susceptible to treatment. While targeting glutamine metabolism presents a promising avenue for pancreatic cancer treatment, it is essential to approach this strategy with caution. Glutamine is vital for the function of normal cells, including those of the immune system. Therefore, therapies that inhibit glutamine metabolism must be carefully balanced to minimize potential side effects and avoid compromising normal cellular functions. 

Dr. Thomas N. Seyfried has addressed pancreatic cancer in his research, emphasizing its metabolic aspects. In an article published in April 2024, Dr. Seyfried and his colleagues discussed the limitations of current genomic-based therapies for pancreatic ductal adenocarcinoma (PDAC) and proposed a metabolic approach to treatment. They highlighted that PDAC cells often exhibit impaired oxidative phosphorylation, leading to a reliance on glucose and glutamine fermentation for energy. This metabolic dependency suggests that targeting these pathways could be a viable therapeutic strategy. 

Dr. Seyfried advocates for interventions such as caloric restriction, fasting, and ketogenic diets to exploit the metabolic vulnerabilities of cancer cells. These approaches aim to reduce glucose availability and elevate ketone bodies, which normal cells can utilize for energy but cancer cells cannot due to their metabolic inflexibility. By simultaneously restricting glucose and glutamine, while inducing therapeutic ketosis, this strategy seeks to selectively target cancer cells while preserving healthy ones. 

end